The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

“It’s important to have a good relationship with a dermatologist who knows about you and your overall health in order to help you make good decisions about biologic treatment,” she add ...

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

With the introduction of biologic therapies into dermatology clinics, nurses will want to become familiar with and comfortable administering biologic agents via the IV, intramuscular (IM), or SC ...

Biologic agents are designed to inhibit key pathogenic steps, providing therapeutic benefit for the treatment of psoriasis. Dermatology nurses must be prepared to integrate biologic agents into ...

“Numerous biologic agents ... are currently available and licensed for treating psoriasis and PsA,” Tai-Li Chen, MD, of the department of dermatology at Taipei Veterans General Hospital in ...

Loss of response to biologics is common ... according to a review published in the Journal of the American Academy of Dermatology. 1 Adalimumab (Humira),, a tumor necrosis factor (TNF)-α ...

Zest provides patients with more personalized, responsive care. Zest’s virtual, high-touch approach is bolstered by patient data to identify optimal prescription regimens, over-the-counter medications ...

particularly the biologics products, with the continued growth of its broad portfolio of medical dermatology solutions, including Klisyri®, Wynzora®, and Seysara®. Almirall’s commercial ...

non-cell-ular platform biologic with the potential to improve patients’ outcomes across a range of challenging diseases and conditions in ophthalmology, neurology, dermatology and others.